Topic

Articles

Draft plan looks beyond the immediate European health challenges.

Long-View Innovation Hopes for Pharma Policy in the EU 

Latest proposal explores boosting the powers of the EMA.

COVID-19 Catalyzing Changes in European Medicines Regulation

Remco Munnik is Associate Director at Iperion, a globally-operating life sciences consultancy firm which is paving the way to digital healthcare, and as such strongly committed to contributing to the actual implementation of the ISO IDMP standards. www.iperion.comRemco.munnik@iperion.com 

The European Medicines Agency (EMA) has published a guide to implementing IDMP data standards that will be ”a game changer” for the life sciences sector. Remco Munnik, who has been working with the EU focus group creating the EU IDMP Implementation Guide version 2, provides the inside track on the implications for life sciences companies.

EMA Launches Data Standards Implementation Guide: The Time to Act is Now

Marc Matar is a Partner, Graham Tatham is a Partner, Rachel Rowbottom is a Director, Sam Calderwood is a Senior Consultant, and Katerina Stavri is a Consultant in 

Life Sciences division based in the company’s London office.

Post-Brexit, the UK’s MHRA is looking to join Project Orbis, a global program to speed up patient access to innovative cancer treatments. This article looks at the implications of Project Orbis for commercialization in the UK and the key considerations for industry in considering the project as a pathway. 

Project Orbis: Implications for Access and Pricing in the UK

 is an independent global pharmaceutical business analyst. 

 is independent adviser at MBM Future Health.

Donald Macarthur and Dr. Meriem Bouslouk-Marx discuss post-approval findings of national committees in Europe charged with deciding the best strategy to use a new COVID-19 vaccine in their populations.

Efficacy Controversy Hits European COVID-19 Vaccine Rollout

Can private sector serve public interests in battling rare diseases?

The Fight for Orphan Drug Research Reform in Europe

's Online and European Editor. He can be reached at jupton@mjhlifesciences.com

Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.

Optimism for the UK’s Life Sciences Future

Sam Pearce, SVP, Head of Europe and International at Jazz Pharmaceuticals, talks about joining the company during a transformative period and how she is working to foster a bold and collaborative culture to expand Jazz’s footprint in Europe and beyond.

Sam Pearce: Joining the Jigsaw Pieces at Jazz

Peter Kohut is Director of Drug Safety at Arriello and an experienced EU QPPV. He began his career in biochemical research, before entering the pharmaceutical industry where he has worked in both clinical trials and post-marketing safety roles. Arriello is a global provider of innovative, high-impact market access, regulatory affairs & pharmacovigilance solutions and services for pharma and biotech firms primarily in Europe and North America.

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.

Navigating the European Market for Medical Cannabis

Cliodhna McDonough is a life sciences lawyer at Fieldfisher.

On December 24, 2020, the UK finally agreed a Trade and Cooperation Agreement (TCA) with the EU. Cliodhna McDonough offers some initial thoughts on the implications of the TCA on the life sciences sector.